BioNTech SE and Bristol Myers Squibb have announced interim results from a global randomized Phase 2 trial evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, in combination with chemotherapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC), regardless of PD-L1 expression levels. The data indicate a confirmed objective response rate of 61.5%, an unconfirmed objective response rate of 71.8%, and a disease control rate of 92.3%. The safety profile was described as manageable. These interim results will be presented at the 2025 San Antonio Breast Cancer Symposium and support dose selection for the ongoing pivotal Phase 3 ROSETTA BREAST-01 trial.